Secretagogue
A growth-hormone-releasing analog examined in preclinical secretagogue research.
Tesamorelin is studied for how the body regulates its own growth hormone. It is a stabilized form of the natural growth-hormone-releasing hormone (GHRH), and in preclinical and metabolic research it is examined as a probe of the growth-hormone axis, including studies with adipose-tissue (including visceral adipose) endpoints.
Type
Synthetic peptide (acylated, 44 residues)
Molecular formula
C221H366N72O67S
Molecular weight
~5,136 g/mol
CAS number
218949-48-5
Amino acids
44
Modification
Full GHRH(1-44) with an N-terminal trans-3-hexenoyl group; C-terminal amide.
A stabilized analogue of human GHRH(1-44) that binds the GHRH receptor (GHRHR), a class B GPCR. The N-terminal trans-3-hexenoyl group distinguishes it from native GHRH.
Research Focus
Studied in GHRH-receptor pharmacology and preclinical metabolic and body-composition research.
Lyophilized
-20°C (-80°C extended)
typically stable 24-36 months desiccated.
Reconstituted
2-8°C short-term
-20°C/-80°C for longer storage.
Avoid freeze-thaw; aliquot; protect from light and moisture. Contains an oxidation-sensitive methionine.
Reviews
Spooner LM. (2012). Ann Pharmacother — Pharmacology and clinical-literature review (HIV-associated lipodystrophy population)
Dhillon S. (2011). Drugs — Clinical-program review (HIV-associated lipodystrophy population)
Tomlinson B, Hu M. (2006). Expert Opin Investig Drugs — Early investigational-profile review
Clinical
Ellis RJ, et al. (2025). J Infect Dis — Neurocognitive-endpoint study, HIV with abdominal obesity
Russo SC, et al. (2024). AIDS — Central-adiposity RCT, contemporary-ART HIV population
Fourman LT, et al. (2020). JCI Insight — Hepatic-transcriptomic-signature substudy, HIV-associated NAFLD
Stanley TL, et al. (2019). Lancet HIV — Liver-fat-endpoint RCT, HIV-associated NAFLD
Clemmons DR, et al. (2017). PLOS ONE — Glycemic and metabolic-endpoint RCT, type 2 diabetes population
Stanley TL, et al. (2014). JAMA — Visceral-fat and liver-fat-endpoint RCT, HIV with abdominal fat
Friedman SD, et al. (2013). JAMA Neurol — Brain-GABA neuroimaging study, mild cognitive impairment / healthy aging
Baker LD, et al. (2012). Arch Neurol — Cognitive-endpoint controlled trial, older adults
Makimura H, et al. (2012). J Clin Endocrinol Metab — Metabolic-endpoint RCT, obesity with reduced GH secretion
Stanley TL, et al. (2012). Clin Infect Dis — Secondary analysis of visceral-fat change vs metabolic markers, HIV population
Falutz J, et al. (2010). J Clin Endocrinol Metab — Pooled abdominal-adiposity analysis, HIV population
Falutz J, et al. (2010). J Acquir Immune Defic Syndr — Abdominal-fat-endpoint RCT and extension, HIV population
Falutz J, et al. (2008). AIDS — Long-term body-composition and safety extension, HIV population
Falutz J, et al. (2007). NEJM — Pivotal RCT of visceral-adiposity and metabolic endpoints, HIV population
Falutz J, et al. (2005). AIDS — Earliest randomized study, HIV population
Research Use Only
These products are intended for research purposes only and are not for human consumption. Not FDA approved. Not intended to diagnose, treat, cure, or prevent any disease.
